Clinical study services
Medeuronet, a medical device consulting firm focused on European market entry, has acquired the clinical study business assets from IROC Science in a private transaction. IROC Science (Zug, Switzerland) will continue to operate, focusing on developing ophthalmology products, collaborating with medeuronet until companies are ready to go to market.
“After collaborating on ophthalmology projects over the past five years, this acquisition of IROC Science’s clinical business makes sense given medeuronet’s growing focus on clinical study services in ophthalmology,” said Kristine Morrill, medeuronet co-founder and lead on clinical studies and medical communications services.
Prof Dr Michael Mrochen, founder and CEO of IROC Science said: “We are looking forward to working together to transition our clients over to the medeuronet team given its strong ability to successfully design, set-up and manage clinical studies in ophthalmology ranging from first-in-human to post-market clinical follow-up studies.”
With the implementation of the new Medical Device Regulation (MDR) in just under a year, medeuronet is increasingly focused on assisting its clients in anticipating the new clinical data requirements that will be necessary to obtain and maintain CE marking.
“There continues to be a great deal of misinformation and uncertainty about the new clinical requirements under MDR” said Ms Morrill. “We are helping our clients chart a practical path through this uncertainty, without significant increases in expenses. We remain positive about the benefits of European market entry and commercialisation and firmly believe that a ‘Europe first’ approach is the right one,” she said.